Radius Health Inc (NASDAQ:RDUS) major shareholder Growth N. V. Biotech bought 50,000 shares of the stock in a transaction on Tuesday, November 14th. The shares were bought at an average price of $26.25 per share, for a total transaction of $1,312,500.00. Following the purchase, the insider now directly owns 5,698,799 shares in the company, valued at approximately $149,593,473.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Shares of Radius Health Inc (NASDAQ:RDUS) traded up $0.36 during trading on Monday, hitting $28.23. The stock had a trading volume of 1,444,205 shares, compared to its average volume of 962,623. The company has a debt-to-equity ratio of 0.53, a quick ratio of 12.79 and a current ratio of 12.87. Radius Health Inc has a 1 year low of $24.66 and a 1 year high of $55.30.
Radius Health (NASDAQ:RDUS) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by ($0.03). The company had revenue of $13.50 million during the quarter, compared to analysts’ expectations of $6.90 million. Radius Health had a negative net margin of 429.45% and a negative return on equity of 90.42%. During the same quarter last year, the firm earned ($1.07) EPS. sell-side analysts predict that Radius Health Inc will post -5.4 earnings per share for the current year.
Several research firms have recently commented on RDUS. Zacks Investment Research raised shares of Radius Health from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. Maxim Group reissued a “positive” rating on shares of Radius Health in a report on Friday, September 29th. They noted that the move was a valuation call. Goldman Sachs Group reissued a “neutral” rating and issued a $45.00 target price on shares of Radius Health in a report on Friday, October 6th. Jefferies Group reiterated a “hold” rating and set a $38.00 target price (up from $34.00) on shares of Radius Health in a research report on Wednesday, August 9th. Finally, BidaskClub downgraded Radius Health from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Three research analysts have rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $51.00.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Principal Financial Group Inc. boosted its holdings in Radius Health by 3.1% in the first quarter. Principal Financial Group Inc. now owns 5,970 shares of the biopharmaceutical company’s stock worth $231,000 after acquiring an additional 180 shares in the last quarter. Ameritas Investment Partners Inc. lifted its holdings in shares of Radius Health by 19.9% during the second quarter. Ameritas Investment Partners Inc. now owns 3,266 shares of the biopharmaceutical company’s stock worth $148,000 after purchasing an additional 541 shares during the period. Cornerstone Capital Management Holdings LLC. lifted its holdings in shares of Radius Health by 4.1% during the second quarter. Cornerstone Capital Management Holdings LLC. now owns 17,605 shares of the biopharmaceutical company’s stock worth $795,000 after purchasing an additional 690 shares during the period. Sei Investments Co. lifted its holdings in shares of Radius Health by 27.7% during the second quarter. Sei Investments Co. now owns 3,180 shares of the biopharmaceutical company’s stock worth $144,000 after purchasing an additional 690 shares during the period. Finally, California Public Employees Retirement System lifted its holdings in shares of Radius Health by 2.3% during the second quarter. California Public Employees Retirement System now owns 71,600 shares of the biopharmaceutical company’s stock worth $3,238,000 after purchasing an additional 1,600 shares during the period.
TRADEMARK VIOLATION WARNING: “Growth N. V. Biotech Purchases 50,000 Shares of Radius Health Inc (NASDAQ:RDUS) Stock” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.dispatchtribunal.com/2017/12/04/radius-health-inc-rdus-major-shareholder-buys-1312500-00-in-stock.html.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.